Oncodesign and Hitgen have initiated a worldwide strategic alliance in Integrated Drug Discovery Services for the identification and progression of new chemical entities, spanning from Hit finding up to preparation of the Investigational New Drug filing.
 
“We are extremely delighted to engage with HitGen, a highly recognized and world leader in DNA-encoded libraries, into this strategic partnership,” said Fabrice Viviani, senior executive vice-president and chief of Oncodesign Services. “We are excited to join our forces and complementary expertise within the DRIVE-for small molecules offer to further gain recognition of our ability to identify and generate together novel pre-clinical candidates ready to progress into the clinic.”
 
Philippe Genne, Chairman, CEO and founder of Oncodesign added, “Through this partnership, we are building an innovative technological continuum aiming to provide clients with a complete service offer in the development of drug candidates. Perfectly complementary with our expertise, HitGen’s technology is positioned upstream on the value chain of Drug Discovery process and, thus, enables us now to generate hits, compounds with desired activity related to the new therapeutic targets. This alliance will support our expansion on the IDDS market, which until now has been reserved for larger Contract Research Organizations (CRO). This agreement gives us an international positioning, including Asia, the US and Europe. The co-branding around the DRIVE -SM offer will be an efficient leverage to generate commercial synergies. The marketing of the IDDS offer is a strategic element for the growth of our service revenue and the achievement of our 2023 objectives.”